Knott David M Jr
Filing Date
Global Rank
#5,178
/ 8,586
▼ 584
Top Industry
Biotechnology
56.8%
3Y Alpha vs SPY
+3.4%
Period ended 3 months ago
Filed May 14, 2026 · 33d
18 quarters · since Dec 2021
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+94.3%
SPY
+78.1%
Annualised alpha
+3.6%
Max drawdown
−43.0%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
76 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
19.7%
−5.0 pts
Top 5
42.7%
−13.4 pts
Top 10
61.3%
−10.6 pts
HHI
650
Diversified−428
Portfolio Trend
18 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 70.6% | $90,016,627 |
| Financial Services | 25.7% | $32,717,921 |
| Technology | 1.7% | $2,207,395 |
| Energy | 0.7% | $861,759 |
| Industrials | 0.3% | $413,235 |
| Consumer Defensive | 0.3% | $404,448 |
| Basic Materials | 0.3% | $323,711 |
| Real Estate | 0.2% | $228,336 |
| Consumer Cyclical | 0.1% | $176,051 |
| Communication Services | 0.1% | $86,268 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
16 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Ltd | +187,835 | 387,835 | $1,016,127 | |
| XERS | Xeris Biopharma Holdings, Inc. | +90,000 | 1,060,000 | $6,148,000 | |
| AGIO | Agios Pharmaceuticals, Inc. | +75,058 | 93,058 | $3,148,152 | |
| HELP | Cybin Inc. | +64,818 | 350,000 | $1,680,000 | |
| TGTX | Tg Therapeutics, Inc. | +45,001 | 90,001 | $2,989,833 | |
| VRDN | Viridian Therapeutics, Inc.DE | +36,000 | 181,000 | $3,540,360 | |
| CNTA | Centessa Pharmaceuticals plc | +35,000 | 39,000 | $1,549,080 | |
| RZLT | Rezolute, Inc. | +30,000 | 370,000 | $1,128,500 | |
| ALKS | Alkermes plc. | +25,000 | 120,000 | $4,243,200 | |
| KURA | Kura Oncology, Inc. | +13,558 | 52,767 | $428,995 | |
| RARE | Ultragenyx Pharmaceutical Inc. | +13,063 | 33,069 | $692,795 | |
| SNDX | Syndax Pharmaceuticals Inc | +7,000 | 422,000 | $9,857,920 | |
| BBIO | BridgeBio Pharma, Inc. | +5,000 | 90,000 | $6,683,400 | |
| OBIO | Orchestra BioMed Holdings, Inc. | +3,651 | 253,651 | $1,078,016 | |
| COGT | Cogent Biosciences, Inc. | +2,000 | 104,000 | $4,002,960 | |
| PTHS | Pelthos Therapeutics Inc. | +1,792 | 21,073 | $442,743 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
13 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| SLDB | Solid Biosciences Inc. | −115,297 | 47,143 | $339,429 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | −69,000 | 120,000 | $2,971,200 | |
| WVE | Wave Life Sciences Ltd. | −50,000 | 40,000 | $290,000 | |
| TVTX | Travere Therapeutics, Inc. | −45,367 | 140,633 | $4,178,206 | |
| RCUS | Arcus Biosciences, Inc. | −40,000 | 81,241 | $1,754,805 | |
| JSPR | Jasper Therapeutics, Inc. | −20,600 | 160,789 | $140,851 | |
| LENZ | LENZ Therapeutics, Inc. | −20,000 | 33,732 | $308,647 | |
| CYTK | Cytokinetics Inc | −10,356 | 23,644 | $1,558,376 | |
| PTGX | Protagonist Therapeutics, Inc | −10,000 | 63,000 | $6,640,200 | |
| BMY | Bristol Myers Squibb Co | −8,378 | 13,622 | $826,174 | |
| ACLX | Arcellx, Inc. | −6,267 | 19,433 | $2,231,297 | |
| BIIB | Biogen Inc. | −2,000 | 4,000 | $733,320 | |
| JNJ | Johnson & Johnson | −2,000 | 4,922 | $1,203,133 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
7 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics, Inc. | 1,600,000 | $5,616,000 | |
| RLMD | Relmada Therapeutics, Inc. | 439,300 | $3,057,528 | |
| ARDX | Ardelyx, Inc. | 207,000 | $1,239,930 | |
| VSTM | Verastem, Inc. | 104,000 | $551,200 | |
| CGEM | Cullinan Therapeutics, Inc. | 24,200 | $343,882 | |
| RAIN | Rain Enhancement Technologies Holdco, Inc. | 101,686 | $258,282 | |
| BRSL | Brightstar Lottery PLC | 2,500 | $31,850 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
10 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CLMT | Calumet, Inc. /DE | 2,214,969 | $44,011,434 | |
| TECX | Tectonic Therapeutic, Inc. | 74,000 | $1,543,640 | |
| BHVN | Biohaven Ltd. | 110,720 | $1,250,028 | |
| NKTR | Nektar Therapeutics | 15,500 | $655,340 | |
| SRRK | Scholar Rock Holding Corp | 13,913 | $612,867 | |
| XENE | Xenon Pharmaceuticals Inc. | 10,962 | $491,316 | |
| FATE | Fate Therapeutics Inc | 365,000 | $357,700 | |
| DAWN | Day One Biopharmaceuticals, Inc. | 25,884 | $241,238 | |
| QURE | uniQure N.V. | 4,000 | $95,720 | |
| FSK | FS KKR Capital Corp | 2,875 | $42,578 | |
| No positions match the current search. | ||||
7 positions ·
$2,207,395 total
· Technology only
· as of Mar 31, 2026
All sectors
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| AAPL |
Apple Inc.
Technology
|
Held | 2,494 | $632,952 | 28.67% | |
| MSFT |
Microsoft Corp
Technology
|
Held | 1,600 | $592,272 | 26.83% | |
| IBM |
International Business Machines Corp
Technology
|
Held | 2,142 | $519,199 | 23.52% | |
| NVDA |
Nvidia Corp
Technology
|
Held | 1,280 | $223,232 | 10.11% | |
| AVGO |
Broadcom Inc.
Technology
|
Held | 710 | $219,752 | 9.96% | |
| CRM |
Salesforce, Inc.
Technology
|
Held | 77 | $14,373 | 0.65% | |
| KD |
Kyndryl Holdings, Inc.
Technology
|
Held | 428 | $5,615 | 0.25% |